Reduction in the Evolution of Murine Type II Collagen-Induced Arthritis by Treatment with Rosiglitazone, a Ligand of the Peroxisome Proliferator-Activated Receptor γ

Salvatore Cuzzocrea, Emanuela Mazzon, Laura Dugo, N. S A Patel, Ivana Serraino, Rosanna Di Paola, Tiziana Genovese, Domenico Britti, Massimo De Maio, Achille P. Caputi, Christoph Thiemermann

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Objective. The peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors related to retinoid, steroid, and thyroid hormone receptors. The thiazolidinedione rosiglitazone is a PPARγ ligand that modulates the transcription of target genes. The aim of this study was to investigate the effects of rosiglitazone on the inflammatory response in mice with collagen-induced arthritis (CIA). Methods. CIA was induced in DBA/1J mice by an intradermal injection of 100 μl of an emulsion of bovine type II collagen (CII; 100 μg) in Freund's complete adjuvant (CFA) at the base of the tail. On day 21, a second injection of CII in CFA was administered. Rosiglitazone (10 mg/kg/day) or vehicle (10% DMSO) was administered beginning on day 25 (arthritis onset) until day 35. Clinical, radiographic, histopathologic, and laboratory assessments were performed. Results. Mice immunized with CII in CFA developed erosive arthritis of the hind paws. Macroscopic evidence of CIA first appeared as periarticular erythema and edema of the hind paws. The incidence of CIA was 100% by day 27 in the CII-challenged mice, and the severity progressed over the 35-day study period. Radiographic evaluation revealed focal resorption of bone. Histopathologic features of CIA included erosion of cartilage at the joint margins. Rosiglitazone treatment ameliorated the clinical signs on days 26-35 and improved the histologic findings in the joint and paw. The degree of oxidative and nitrosative damage was significantly reduced in rosiglitazone-treated mice, as indicated by elevation of malondialdehyde levels, formation of nitrotyrosine, and activation of poly(ADP-ribose) polymerase. Plasma levels of the proinflammatory cytokines tumor necrosis factor, interleukin-1β, and interleukin-6 were also significantly reduced by rosiglitazone treatment. Conclusion. These data demonstrate that rosiglitazone exerts an antiinflammatory effect on chronic inflammation and is able to ameliorate the tissue damage associated with CIA.

Original languageEnglish
Pages (from-to)3544-3556
Number of pages13
JournalArthritis and Rheumatism
Volume48
Issue number12
DOIs
Publication statusPublished - Dec 2003

Fingerprint

rosiglitazone
Peroxisome Proliferator-Activated Receptors
Experimental Arthritis
Ligands
Therapeutics
Arthritis
Joints
Thyroid Hormone Receptors
Intradermal Injections
Inbred DBA Mouse
Collagen Type II
Poly(ADP-ribose) Polymerases
Freund's Adjuvant
Retinoids
Erythema
Bone Resorption
Cytoplasmic and Nuclear Receptors
Dimethyl Sulfoxide
Emulsions
Malondialdehyde

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Reduction in the Evolution of Murine Type II Collagen-Induced Arthritis by Treatment with Rosiglitazone, a Ligand of the Peroxisome Proliferator-Activated Receptor γ. / Cuzzocrea, Salvatore; Mazzon, Emanuela; Dugo, Laura; Patel, N. S A; Serraino, Ivana; Di Paola, Rosanna; Genovese, Tiziana; Britti, Domenico; De Maio, Massimo; Caputi, Achille P.; Thiemermann, Christoph.

In: Arthritis and Rheumatism, Vol. 48, No. 12, 12.2003, p. 3544-3556.

Research output: Contribution to journalArticle

Cuzzocrea, S, Mazzon, E, Dugo, L, Patel, NSA, Serraino, I, Di Paola, R, Genovese, T, Britti, D, De Maio, M, Caputi, AP & Thiemermann, C 2003, 'Reduction in the Evolution of Murine Type II Collagen-Induced Arthritis by Treatment with Rosiglitazone, a Ligand of the Peroxisome Proliferator-Activated Receptor γ', Arthritis and Rheumatism, vol. 48, no. 12, pp. 3544-3556. https://doi.org/10.1002/art.11351
Cuzzocrea, Salvatore ; Mazzon, Emanuela ; Dugo, Laura ; Patel, N. S A ; Serraino, Ivana ; Di Paola, Rosanna ; Genovese, Tiziana ; Britti, Domenico ; De Maio, Massimo ; Caputi, Achille P. ; Thiemermann, Christoph. / Reduction in the Evolution of Murine Type II Collagen-Induced Arthritis by Treatment with Rosiglitazone, a Ligand of the Peroxisome Proliferator-Activated Receptor γ. In: Arthritis and Rheumatism. 2003 ; Vol. 48, No. 12. pp. 3544-3556.
@article{f438f087f0894afa8c699ea7d5eb45c4,
title = "Reduction in the Evolution of Murine Type II Collagen-Induced Arthritis by Treatment with Rosiglitazone, a Ligand of the Peroxisome Proliferator-Activated Receptor γ",
abstract = "Objective. The peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors related to retinoid, steroid, and thyroid hormone receptors. The thiazolidinedione rosiglitazone is a PPARγ ligand that modulates the transcription of target genes. The aim of this study was to investigate the effects of rosiglitazone on the inflammatory response in mice with collagen-induced arthritis (CIA). Methods. CIA was induced in DBA/1J mice by an intradermal injection of 100 μl of an emulsion of bovine type II collagen (CII; 100 μg) in Freund's complete adjuvant (CFA) at the base of the tail. On day 21, a second injection of CII in CFA was administered. Rosiglitazone (10 mg/kg/day) or vehicle (10{\%} DMSO) was administered beginning on day 25 (arthritis onset) until day 35. Clinical, radiographic, histopathologic, and laboratory assessments were performed. Results. Mice immunized with CII in CFA developed erosive arthritis of the hind paws. Macroscopic evidence of CIA first appeared as periarticular erythema and edema of the hind paws. The incidence of CIA was 100{\%} by day 27 in the CII-challenged mice, and the severity progressed over the 35-day study period. Radiographic evaluation revealed focal resorption of bone. Histopathologic features of CIA included erosion of cartilage at the joint margins. Rosiglitazone treatment ameliorated the clinical signs on days 26-35 and improved the histologic findings in the joint and paw. The degree of oxidative and nitrosative damage was significantly reduced in rosiglitazone-treated mice, as indicated by elevation of malondialdehyde levels, formation of nitrotyrosine, and activation of poly(ADP-ribose) polymerase. Plasma levels of the proinflammatory cytokines tumor necrosis factor, interleukin-1β, and interleukin-6 were also significantly reduced by rosiglitazone treatment. Conclusion. These data demonstrate that rosiglitazone exerts an antiinflammatory effect on chronic inflammation and is able to ameliorate the tissue damage associated with CIA.",
author = "Salvatore Cuzzocrea and Emanuela Mazzon and Laura Dugo and Patel, {N. S A} and Ivana Serraino and {Di Paola}, Rosanna and Tiziana Genovese and Domenico Britti and {De Maio}, Massimo and Caputi, {Achille P.} and Christoph Thiemermann",
year = "2003",
month = "12",
doi = "10.1002/art.11351",
language = "English",
volume = "48",
pages = "3544--3556",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Reduction in the Evolution of Murine Type II Collagen-Induced Arthritis by Treatment with Rosiglitazone, a Ligand of the Peroxisome Proliferator-Activated Receptor γ

AU - Cuzzocrea, Salvatore

AU - Mazzon, Emanuela

AU - Dugo, Laura

AU - Patel, N. S A

AU - Serraino, Ivana

AU - Di Paola, Rosanna

AU - Genovese, Tiziana

AU - Britti, Domenico

AU - De Maio, Massimo

AU - Caputi, Achille P.

AU - Thiemermann, Christoph

PY - 2003/12

Y1 - 2003/12

N2 - Objective. The peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors related to retinoid, steroid, and thyroid hormone receptors. The thiazolidinedione rosiglitazone is a PPARγ ligand that modulates the transcription of target genes. The aim of this study was to investigate the effects of rosiglitazone on the inflammatory response in mice with collagen-induced arthritis (CIA). Methods. CIA was induced in DBA/1J mice by an intradermal injection of 100 μl of an emulsion of bovine type II collagen (CII; 100 μg) in Freund's complete adjuvant (CFA) at the base of the tail. On day 21, a second injection of CII in CFA was administered. Rosiglitazone (10 mg/kg/day) or vehicle (10% DMSO) was administered beginning on day 25 (arthritis onset) until day 35. Clinical, radiographic, histopathologic, and laboratory assessments were performed. Results. Mice immunized with CII in CFA developed erosive arthritis of the hind paws. Macroscopic evidence of CIA first appeared as periarticular erythema and edema of the hind paws. The incidence of CIA was 100% by day 27 in the CII-challenged mice, and the severity progressed over the 35-day study period. Radiographic evaluation revealed focal resorption of bone. Histopathologic features of CIA included erosion of cartilage at the joint margins. Rosiglitazone treatment ameliorated the clinical signs on days 26-35 and improved the histologic findings in the joint and paw. The degree of oxidative and nitrosative damage was significantly reduced in rosiglitazone-treated mice, as indicated by elevation of malondialdehyde levels, formation of nitrotyrosine, and activation of poly(ADP-ribose) polymerase. Plasma levels of the proinflammatory cytokines tumor necrosis factor, interleukin-1β, and interleukin-6 were also significantly reduced by rosiglitazone treatment. Conclusion. These data demonstrate that rosiglitazone exerts an antiinflammatory effect on chronic inflammation and is able to ameliorate the tissue damage associated with CIA.

AB - Objective. The peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors related to retinoid, steroid, and thyroid hormone receptors. The thiazolidinedione rosiglitazone is a PPARγ ligand that modulates the transcription of target genes. The aim of this study was to investigate the effects of rosiglitazone on the inflammatory response in mice with collagen-induced arthritis (CIA). Methods. CIA was induced in DBA/1J mice by an intradermal injection of 100 μl of an emulsion of bovine type II collagen (CII; 100 μg) in Freund's complete adjuvant (CFA) at the base of the tail. On day 21, a second injection of CII in CFA was administered. Rosiglitazone (10 mg/kg/day) or vehicle (10% DMSO) was administered beginning on day 25 (arthritis onset) until day 35. Clinical, radiographic, histopathologic, and laboratory assessments were performed. Results. Mice immunized with CII in CFA developed erosive arthritis of the hind paws. Macroscopic evidence of CIA first appeared as periarticular erythema and edema of the hind paws. The incidence of CIA was 100% by day 27 in the CII-challenged mice, and the severity progressed over the 35-day study period. Radiographic evaluation revealed focal resorption of bone. Histopathologic features of CIA included erosion of cartilage at the joint margins. Rosiglitazone treatment ameliorated the clinical signs on days 26-35 and improved the histologic findings in the joint and paw. The degree of oxidative and nitrosative damage was significantly reduced in rosiglitazone-treated mice, as indicated by elevation of malondialdehyde levels, formation of nitrotyrosine, and activation of poly(ADP-ribose) polymerase. Plasma levels of the proinflammatory cytokines tumor necrosis factor, interleukin-1β, and interleukin-6 were also significantly reduced by rosiglitazone treatment. Conclusion. These data demonstrate that rosiglitazone exerts an antiinflammatory effect on chronic inflammation and is able to ameliorate the tissue damage associated with CIA.

UR - http://www.scopus.com/inward/record.url?scp=10744224449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744224449&partnerID=8YFLogxK

U2 - 10.1002/art.11351

DO - 10.1002/art.11351

M3 - Article

C2 - 14674008

AN - SCOPUS:10744224449

VL - 48

SP - 3544

EP - 3556

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 12

ER -